JEVTANA KIT®

Drug Information Related Patent

Hold Company

SANOFI AVENTIS US

Learn More

Dosage and Administration

SOLUTION;INTRAVENOUS

Specification

60MG/1.5ML (40MG/ML)

Indication

JEVTANA KIT® is indicated for patients with metastatic castration-resistant prostate cancer in combination with prednisone.

Use

Instructions for Use

API

CABAZITAXEL

API Structure

We Supply

CABAZITAXEL

Note:

In-house Standard
Facility GMP
USMF/CDE/DMF/FDA/EMA

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
10583110	2030/10/27
10716777	2030/10/27
7241907	2025/12/10
7241907*PED	2026/6/10
8927592	2030/10/27
8927592*PED	2031/4/27

API Patent

Patent No	Expiration Date
7241907	2025/12/10
7241907*PED	2026/6/10

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION